A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.

A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Item

http://www.wikidata.org/entity/Q37310514

Q37310514

about

Antibody therapies for lymphoma in children Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead A novel trial of topotecan, ifosfamide, and carboplatin (TIC) in children with recurrent solid tumors.Immunotherapy of childhood cancer: from biologic understanding to clinical application.Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantatio Clinical outcome of relapsed or refractory burkitt lymphoma and mature B-cell lymphoblastic leukemia in children and adolescents.Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children's Oncology Group study A5962.Children's Oncology Group's 2013 blueprint for research: non-Hodgkin lymphoma.Treatment outcomes in children with Burkitt lymphoma and L3 acute lymphoblastic leukemia treated using the lymphoma malignancy B protocol at a single institution.Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults?Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective "Lymphomes Malins B" protocols. A Société Française des Cancers de l'Enfant study.Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology Group Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report.Immunotherapy targets in pediatric cancer.Molecular profiling of childhood cancer: Biomarkers and novel therapies Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia UCH-L1 is induced in germinal center B cells and identifies patients with aggressive germinal center diffuse large B-cell lymphoma.Antibody therapy of pediatric B-cell lymphoma Advanced targeted, cell and gene-therapy approaches for pediatric hematological malignancies: results and future perspectives Pharmacokinetics of Chemotherapeutic Drugs in Pediatric Patients With Down Syndrome and Leukemia.TAM receptors in leukemia: expression, signaling, and therapeutic implications.Immunotherapy for pediatric leukemia.Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia.Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia.The future role of monoclonal antibody therapy in childhood acute leukaemias.Mature B-cell lymphoma and leukemia in children and adolescents-review of standard chemotherapy regimen and perspectives.XI. How to treat children and adolescents with relapsed non-Hodgkin lymphoma?Management of Non-Hodgkin Lymphoma: ICMR Consensus Document.Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia.Novel approaches to pediatric leukemia treatment.Recent molecular and therapeutic advances in B-cell non-Hodgkin lymphoma in children.Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.Dual inhibition of histone deacetylases and phosphoinositide 3-kinases: effects on Burkitt lymphoma cell growth and migration.Childhood, adolescent and young adult non-Hodgkin lymphoma: state of the science.Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101.Histone deacetylase inhibitor potentiates chemotherapy-induced apoptosis through Bim upregulation in Burkitt's lymphoma cells.Relapsed/refractory pediatric B-cell non-Hodgkin lymphoma treated with rituximab combination therapy: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group.Safety and efficacy of intrathecal rituximab in children with B cell lymphoid CD20+ malignancies: An international retrospective study.

P2860

Q24186437-62CD2FDA-B4DF-4D12-9FF5-FE1C87353333 Q26746934-7DB9648D-8118-42A4-8152-17C584FD0FBC Q26797513-6EDDB702-DF85-4D23-AE4A-B332FFC3DA9D Q33418620-C33236AE-1784-4E2D-8B9D-7914412988D1 Q33752982-0D69FBE3-C73B-4339-97C3-E0DD0B514857 Q34080843-F7FCF144-B76F-4601-B501-6F4BBA06FB81 Q34202277-40CE209B-3133-4706-8EE4-84DA6AED002B Q34386029-09361F52-330B-478D-9839-B7FE6331595A Q34773043-E7BDD96C-FCB3-4CC5-9C76-E7893C60F8E9 Q35083003-CD168C34-1781-4879-B8CC-277D9FC944BA Q35084407-8DBDBC09-2F7C-4F29-B2CB-9C222543AAE0 Q35237511-7A5A17F0-6E17-4692-AD2A-7A4FFFD168B3 Q35669884-0D13389E-3F6C-414D-BCC0-924762147C00 Q35953635-77F23DD4-739B-491E-B349-6841C763791D Q35963027-02550178-E264-4652-A6ED-31083A34937D Q35971029-AF506C4E-9EC4-460E-80D5-4ACBDEF9B946 Q36250783-C20C1341-B717-43AC-93CC-9299371D0B52 Q36339717-71384A42-B086-4614-ABCF-A83CBD2EF464 Q36727872-EE96C109-2AE6-495D-A648-0371C0FBA6C3 Q36732959-9B0DF3C7-9A36-445D-9999-4CDD04B9FD82 Q36804215-E6086658-F60A-4BBD-AA80-F6FA3372EAFF Q36828315-0F56953A-6CB9-4245-99BD-D105A294D2D8 Q36865209-3A813C10-5A08-4C07-A84F-6D65BC93D397 Q36968163-17DF877C-5D65-46CD-A5A2-C011097F03D1 Q37613872-3A4712EF-C686-4FBE-99FD-24896EFF30A6 Q37977133-3C0C61A5-01A2-4609-AF63-978B791B3E55 Q38033600-E7666E43-61B7-4F69-AE6B-353053F92DAA Q38097544-A3EAF612-8398-40F6-BD5C-23D8B3CF7BBC Q38115231-41E4877C-2A37-428B-999F-269BF34423C1 Q38371659-8C1D4010-3567-49E2-AB85-B1697A8CF159 Q38474121-F00A5222-2077-4968-BEEA-30D7FF1C4F43 Q38500371-2A150DB6-DCE7-4C6C-B6C8-F8E795FAA20C Q38782141-1D01FEEF-75D3-4372-9984-CA28AFA155F2 Q38803361-50788073-9E77-4D08-A250-7DDD205E335E Q38819975-88BB265B-276A-4BC5-A6A6-3A0B33D79095 Q38822525-FC18D070-C483-430D-88AC-97E712C04D95 Q39020172-CB0054D8-7A97-4F35-AABC-6CF79B516B5E Q39434896-B398E5B1-E79D-426E-9F0C-D057D9974F46 Q40695241-7FDC8474-6EA9-42BC-9BE9-078CDF89EF3C Q40912836-F03D2F48-2080-42BE-B6F8-9D0E02A965A0

P2860

A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Item

http://www.wikidata.org/entity/Q37310514

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs